[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "DW News Interview", "description": "Thanks as always to DW news", "link": "https://www.youtube.com/watch?v=1_3bRvsjvy0", "date_published": "2020-11-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Second Vitamin D clinical trial, positive results", "description": "Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)\n\nhttps://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065.full\n\n\nIt has been observed that vitamin D-deficient individuals \nhave increased COVID-19 risk and mortality\n\nPharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323:1824\u201336. doi: 10.1001/jama.2020.6019\n\nThe role of vitamin D in the prevention of coronavirus disease infection and mortality. \n\nAging Clin Exp Res 2020;32:1195\u20138. doi: 10.1007/s40520-020-01570-8 \n\nAssociation of vitamin D status and other clinical characteristics with COVID-19 test results. \n\nJAMA Netw Open 2020;3:e2019722. (Published 3 Sep 2020).doi: 10.1001/jamanetworkopen.2020.19722 \n\nImmunomodulatory role and protective effect of vitamin D against other viral infections\n\nVitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;15:356:i6583. doi: 10.1136/bmj.i6583 \n\nAn intervention study with calcifediol noticed a reduction in requirement for intensive care among hospitalised patients for COVID19\n\nEffect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study.\n\nJ Steroid Biochem Mol Biol 2020;203:105751. doi: 10.1016/j.jsbmb.2020.105751\n \n50 patients treated with calcifediol, one required admission to the ICU (2%), no deaths\n\n26 untreated patients, 13 required admission (50 %) to the ICU, 2 deaths\n\nImmune-modulatory effect of vitamin D is likely to be observed at 25(OH)D levels, which are considered higher than that required for its skeletal effects\n\nVitamin D to prevent COVID-19: recommendations for the design of clinical trials. Febs J2020;287:3689\u201392. doi: 10.1111/febs.15534 \n\nPositive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults.\n\nBMC Res Notes 2012;5:575. doi: 10.1186/1756-0500-5-575\n\nVitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.\n\n PLoS One 2020;15:e0239799.doi: 10.1371/journal.pone.0239799 \n\nAim\n\nhttps://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065.full\n\nEffect of high dose, oral cholecalciferol supplementation on SARS-CoV-2 viral clearance\n\nFirst cholecalciferol intervention study for asymptomatic and mildly symptomatic SARS-CoV-2 positive individuals\n\n\nDesign\n\nRandomised, placebo-controlled.\n\nParticipants\n\nAsymptomatic or mildly symptomatic SARS-CoV-2 \n\nRNA positive vitamin D deficient (25(OH) D less than 20 ng/ml)\n\nCalcifediol, calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D3\n\nPre intervention baseline serum 25(OH) D\n\nIntervention group, 8.6 ng/ml\n\nControl group, 9.54 ng/ml (p=0.730)\n\n10 out of 16 patients could achieve 25(OH)D more than 50 ng/ml by \nday-7\n\nAnother two by day-14\n\nOutcome measure\n\nProportion of patients with SARS-CoV-2 RNA negative before day-21\n\nChange in inflammatory markers\n\nIntervention group (n=16)\n\n60 000 IU of cholecalciferol (oral nano-liquid droplets) for 7 days\n\nTherapeutic target 25(OH)D more than 50 ng/ml\n\nCholecalciferol supplementation was continued for those with 25(OH)D less than 50 ng/ml\n\nFibrinogen levels significantly decreased with cholecalciferol supplementation \n\n10 (62.5%) participants became SARS-CoV-2 RNA negative\n\nControl group (n=24)\n\nPlacebo\n\n5 (20.8%) participants became SARS-CoV-2 RNA negative (p less than 0.018)\n\nBoth groups\n\nPatients requiring invasive ventilation or with significant comorbidities were excluded\n\n25(OH)D levels were assessed at day 7\n\nRegular measurements of: SARS-CoV-2 RNA, fibrinogen, D-dimer, procalcitonin, CRP, ferritin\n\nImprovements\n\nCalcifediol would have been better\n\nLittle and often for prevention", "link": "https://www.youtube.com/watch?v=7H2c0Zm6PFw", "date_published": "2020-11-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "MMR vaccine and COVID immunity", "description": "Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients\n\nhttps://mbio.asm.org/content/11/6/e02628-20\n\nThe measles-mumps-rubella (MMR) vaccine\n\nTheorized to provide protection against coronavirus disease\n\nTo determine whether any MMR IgG titers are inversely correlated with covid severity\n\nComparing MMR titers to recent COVID-19 severity levels.\n\nThe MMR II group\n\n50 subjects who would primarily have MMR antibodies from the MMR II vaccine\n\nComparison group\n\n30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II\n\nIncluding prior measles, mumps, and/or rubella illnesses\n\nResults in the MMR group\n\nSignificant inverse correlation (rs\u2009=\u2009\u22120.71, P\u2009less than\u20090.001) \n\nBetween mumps virus titers and COVID-19 severity\n\nResults in the comparison group\n\nThere were no significant correlations between mumps IgG titers and severity in the comparison group\n\nResults in both groups\n\nNo correlation between between severity and measles or rubella titers in either group\n\nScale of the observation\n\nMumps titers of 134 to 300\u2009arbitrary units (AU)/ml (n\u2009=\u20098), functionally immune or asymptomatic\n\nLess than 134, (n=17) all had mild symptoms\n\nLess than 75, (n=11) all had moderate symptoms\n\nLess than 32, all who had been hospitalized and had required oxygen\n\nOur results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity\n\nFour important points\n\nYoung children are largely spared from severe disease\n\nSecond, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries\n\nMany people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves\n\nNearly half of people who test positive for COVID-19 are asymptomatic\n\nMechanism of action\n\nSequence homology between both mumps and measles and rubella with SARS-CoV-2\n\nAfter two doses\n\n97% protected against measles\n\n88% against mumps\n\n97% against rubella\n\nNHS site\n\nhttps://www.nhs.uk/conditions/vaccinations/mmr-vaccine/\n\nBorn between 1970 and 1979, as you may have only been vaccinated against measles\n\nBorn between 1980 and 1990, as you may not be protected against mumps\nBradford Hill\nStrength of association\nConsistency\nReproducibility\nSpecificity\nTemporality\nBiological gradient, dose response\nPlausibility\nCoherence with lab findings\nExperiment\nReversibility", "link": "https://www.youtube.com/watch?v=zdAPgglDJAU", "date_published": "2020-11-22 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]